| Attribute |
Value |
| 52 Week Change |
-0.5420168 |
| Address1 |
9,000 Virginia Manor Road |
| Address2 |
Suite 200 |
| All Time High |
1,308.0 |
| All Time Low |
1.55 |
| Ask |
6.69 |
| Ask Size |
2 |
| Audit Risk |
7 |
| Average Daily Volume10 Day |
101,070 |
| Average Daily Volume3 Month |
103,455 |
| Average Volume |
103,455 |
| Average Volume10Days |
101,070 |
| Beta |
1.421 |
| Bid |
5.46 |
| Bid Size |
2 |
| Board Risk |
7 |
| Book Value |
7.406 |
| City |
Beltsville |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
8 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
6.23 |
| Current Ratio |
4.606 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
9.9 |
| Day Low |
5.9 |
| Debt To Equity |
18.39 |
| Display Name |
NextCure |
| Earnings Timestamp End |
1,754,308,800 |
| Earnings Timestamp Start |
1,753,873,140 |
| Ebitda |
-54,285,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
0.312 |
| Enterprise Value |
-16,955,630 |
| Eps Current Year |
-7.32333 |
| Eps Forward |
-8.31 |
| Eps Trailing Twelve Months |
-18.61 |
| Esg Populated |
0 |
| Exchange |
NMS |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
5.0407 |
| Fifty Day Average Change |
1.1893001 |
| Fifty Day Average Change Percent |
0.23593947 |
| Fifty Two Week Change Percent |
-54.20168 |
| Fifty Two Week High |
15.74 |
| Fifty Two Week High Change |
-9.51 |
| Fifty Two Week High Change Percent |
-0.60419315 |
| Fifty Two Week Low |
1.55 |
| Fifty Two Week Low Change |
4.6800003 |
| Fifty Two Week Low Change Percent |
3.019355 |
| Fifty Two Week Range |
1.55 - 15.74 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,557,408,600,000 |
| Float Shares |
2,259,836 |
| Forward Eps |
-8.31 |
| Forward P E |
-0.7496991 |
| Free Cashflow |
-29,195,876 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
40 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,782,864,000 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.14803 |
| Held Percent Institutions |
0.62399 |
| Implied Shares Outstanding |
3,612,096 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,752,451,200 |
| Last Split Factor |
1:12 |
| Long Business Summary |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. |
| Long Name |
NextCure, Inc. |
| Market |
us_market |
| Market Cap |
22,503,358 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_321460821 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-54,664,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
7,874,369 |
| Number Of Analyst Opinions |
3 |
| Open |
9.255 |
| Operating Cashflow |
-49,982,000 |
| Operating Margins |
0.0 |
| Overall Risk |
6 |
| Payout Ratio |
0.0 |
| Phone |
240 399 4900 |
| Previous Close |
2.18 |
| Price Eps Current Year |
-0.8507059 |
| Price Hint |
2 |
| Price To Book |
0.8412098 |
| Profit Margins |
0.0 |
| Quick Ratio |
4.418 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
4.05 |
| Regular Market Change Percent |
185.77985 |
| Regular Market Day High |
9.9 |
| Regular Market Day Low |
5.9 |
| Regular Market Day Range |
5.9 - 9.9 |
| Regular Market Open |
9.255 |
| Regular Market Previous Close |
2.18 |
| Regular Market Price |
6.23 |
| Regular Market Time |
1,784,040,438 |
| Regular Market Volume |
80,078,417 |
| Return On Assets |
-0.66712 |
| Return On Equity |
-1.32405 |
| Sand P52 Week Change |
0.20365608 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
6 |
| Shares Outstanding |
3,612,096 |
| Shares Percent Shares Out |
0.043899998 |
| Shares Short |
158,592 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
68,687 |
| Short Name |
NextCure, Inc. |
| Short Percent Of Float |
0.043899998 |
| Short Ratio |
0.89 |
| Source Interval |
15 |
| State |
MD |
| Symbol |
NXTC |
| Target High Price |
25.0 |
| Target Low Price |
15.0 |
| Target Mean Price |
19.33333 |
| Target Median Price |
18.0 |
| Total Cash |
29,743,000 |
| Total Cash Per Share |
8.234 |
| Total Debt |
4,913,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-18.61 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
9.555805 |
| Two Hundred Day Average Change |
-3.3258052 |
| Two Hundred Day Average Change Percent |
-0.34804028 |
| Type Disp |
Equity |
| Volume |
80,078,417 |
| Website |
https://www.nextcure.com |
| Zip |
20,705 |